REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
Condition: Treatment of Acute Coronary Syndrome (ACS).
MeSH terms: Acute Coronary Syndrome; Syndrome
Study type: Observational

Summary: 
      REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients
      treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital
      after an acute coronary syndrome (ACS) event, to be conducted in Belgium and Luxembourg.

      Primary objective is to evaluate the actual treatment persistence with oral antiplatelets
      (OAP) after an ACS in the clinical practice in Belgium and Luxembourg.

      The main secondary objectives are to describe the most frequent reasons for OAP treatment
      switch, discontinuation or reinitiation; to identify the decisionmakers in the OAP treatment
      changes and to characterize the patient profile in terms of demographics, diagnosis,
      management strategies, comorbidities and concomitant medications to identify any association
      between patient profile and treatment duration.
    

Detailed description: 
      Treatment of acute coronary syndrome (ACS) with oral antiplatelets (OAPs) is recommended for
      up to 12 months unless discontinuation is clinically indicated. Early discontinuation could
      result in an increased risk of cardiovascular death or myocardial infarction due to the
      patient's underlying disease.

      There are no robust data allowing to evaluate the treatment persistence with OAPs after ACS
      in the current practice in Belgium and Luxembourg at this time. It is currently unclear as to
      why patients discontinue, switch or reinitiate treatment and upon whose advice. A
      non-interventional study is needed to obtain reliable data on treatment persistence and
      reasons for discontinuation, switch or reinitiation of treatment.

      REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients
      treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital
      after an ACS event, to be conducted in Belgium and Luxembourg. Primary objective is to
      evaluate the actual treatment persistence with OAPs after an ACS in the clinical practice in
      Belgium and Luxembourg. The main secondary objectives are to describe the most frequent
      reasons for OAP treatment switch, discontinuation or reinitiation; to identify the
      decisionmakers in the OAP treatment changes and to characterize the patient profile in terms
      of demographics, diagnosis, management strategies, comorbidities and concomitant medications
      to identify any association between patient profile and treatment duration.

      The target sample size of the study is 500 patients.
    

Intervention name(s): ACS patients treated with OAP
Intervention type(s): Drug
Intervention description(s): Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
Observational model: Case-Only
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Male and female patients from Belgium and Luxembourg, aged 18 years or more , discharged
        alive from hospital to home following an acute coronary syndrome (ACS) and who were treated
        with an oral antiplatelet (OAP) (ticagrelor, prasugrel or clopidogrel) after an acute
        coronary syndrome (ACS) event (Unstable Angina (UA), ST-elevation myocardial infarction
        (STEMI) or non-STEMI(NSTEMI)).
      
Keywords: Acute Coronary Syndrome (ACS); Oral antiplatelets (ticagrelor, prasugrel, clopidogrel) (OAP); Treatment persistence.